TEL AVIV, Israel--(BUSINESS WIRE)--Compugen Ltd. (NASDAQ:
CGEN) today announced that it will present aspects of its immune
checkpoint related research at two oncology conferences this month.
Galit Rotman, PhD, Chief Scientist of Therapeutics at Compugen, will
deliver an oral presentation at the Immune
Checkpoint Inhibitors conference to be held from March 24-26 in
Boston. Dr. Rotman’s talk titled Novel Immune Checkpoints as Antibody
Targets for Cancer Immunotherapy is part of a session named Validate
Novel Pathways For Blockade Therapy. In her talk, Dr. Rotman will
present experimental data demonstrating the immunomodulatory function of
selected Compugen-discovered novel immune checkpoints as target
candidates for cancer immunotherapy.
In addition, Dr. Rotman will participate in a panel discussion on
immuno-oncology at the Phacilitate
Oncology Leaders’ Forum on March 24, also taking place in Boston.
About Compugen’s Programs for Cancer Immunotherapy
Compugen’s cancer immunotherapy programs are based on eleven novel
predicted B7/CD28-like immune checkpoint candidates and four novel
immunomodulators distinct from the B7/CD28-like proteins, all of which
were initially predicted in silico by Compugen. Immune
checkpoints, including inhibitory receptors and ligands, are
immunomodulatory proteins which are crucial for the maintenance of
self-tolerance (the prevention of autoimmunity) and for the protection
of tissues from damage during an immune response. Immune checkpoints are
"hijacked" by tumors to block the ability of the immune system to
destroy the tumor cells. Therapeutic blockade of immune checkpoints can
boost anti-tumor immunity, enabling the patient’s immune system to
recognize and attack the tumor cells, and mount durable anti-tumor
responses leading to tumor destruction.
About Compugen
Compugen is a leading drug discovery company focused on monoclonal
antibodies and therapeutic proteins to address important unmet needs in
the fields of oncology and immunology. The Company utilizes a broad and
continuously growing integrated infrastructure of proprietary scientific
understandings and predictive platforms, algorithms, machine learning
systems and other computational biology capabilities for the in
silico (by computer) prediction and selection of novel drug target
candidates, which are then advanced in its Pipeline Program. The
discovery and development of monoclonal antibody therapeutic candidates
against selected Compugen-discovered novel target candidates is
performed by Compugen’s wholly-owned U.S. subsidiary located in South
San Francisco. The Company's business model includes collaborations
covering the further development and commercialization of product
candidates at various stages from its Pipeline Program and various forms
of research and discovery agreements, in both cases providing Compugen
with potential milestone payments and royalties on product sales or
other forms of revenue sharing. For additional information, please visit
Compugen's corporate website at www.cgen.com.
Forward Looking Statement
This press release contains “forward-looking statements” within the
meaning of the Private Securities Litigation Reform Act of 1995.
Forward-looking statements can be identified by the use of terminology
such as “will,” “may,” “expects,” “anticipates,” “believes,” and
“intends,” and describe opinions about future events and include
statements related to the potential of Compugen-discovered novel immune
checkpoints as targets for cancer immunotherapy. These forward-looking
statements involve known and unknown risks and uncertainties that may
cause the actual results, performance or achievements of Compugen to be
materially different from any future results, performance or
achievements expressed or implied by such forward-looking statements.
Some of these and other factors are discussed in the "Risk Factors"
section of Compugen’s most recent Annual Report on Form 20-F as filed
with the Securities and Exchange Commission as well as other documents
that may be subsequently filed by Compugen from time to time with the
Securities and Exchange Commission. In addition, any forward-looking
statements represent Compugen’s views only as of the date of this
release and should not be relied upon as representing its views as of
any subsequent date. Compugen does not assume any obligation to update
any forward-looking statements unless required by law.